CAMP4 Therapeutics
Kevin Xiong has worked in a variety of roles since 2009. Kevin began their career as a Tutor at Kumon North America, Inc. in 2009. In 2016, they became a Special Volunteer at the National Institute of Environmental Health Sciences (NIEHS). From 2017-2019, they worked as a Research Associate in the Rosas Laboratory at Brigham and Women's Hospital, where they studied the therapeutic effects of Mesenchymal Stromal Cells (MSCs) in an experimental fibrotic inflammatory setting in mice and discovered the importance of CD148 deficiency in regulating certain signaling and autophagy pathways. Most recently, they have been a Senior Research Associate and Research Associate II at CAMP4 Therapeutics.
Kevin Xiong attended Acton Boxborough Regional High School from 2009 to 2013, where they earned a High School diploma in General Studies. Kevin then pursued a Bachelor of Science in Bioengineering and Biomedical Engineering at the University of Maryland, graduating in 2017.
CAMP4 Therapeutics
1 followers
CAMP4 Therapeutics is pioneering a new approach to upregulate genes by targeting regulatory RNA using programmable oligonucleotide therapeutics.